ID
34754
Beschrijving
Vildagliptin Veresus Liraglutide - Patient Preference After Receiving Both Medications; ODM derived from: https://clinicaltrials.gov/show/NCT01518101
Link
https://clinicaltrials.gov/show/NCT01518101
Trefwoorden
Versies (1)
- 26-01-19 26-01-19 -
Houder van rechten
See clinicaltrials.gov
Geüploaded op
26 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Type 2 Diabetes NCT01518101
Eligibility Type 2 Diabetes NCT01518101
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
Acute Disease
Datatype
boolean
Alias
- UMLS CUI [1]
- C0001314
Beschrijving
Kidney Diseases | Creatinine measurement, serum | Glomerular Filtration Rate
Datatype
boolean
Alias
- UMLS CUI [1]
- C0022658
- UMLS CUI [2]
- C0201976
- UMLS CUI [3]
- C0017654
Beschrijving
Medical contraindication Gliptins | Medical contraindication Glucagon-Like Peptide Analogue
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1301624
- UMLS CUI [1,2]
- C1827106
- UMLS CUI [2,1]
- C1301624
- UMLS CUI [2,2]
- C0014361
- UMLS CUI [2,3]
- C0243071
Beschrijving
Dipeptidyl-Peptidase IV Inhibitors | GLP-1 Mimetics
Datatype
boolean
Alias
- UMLS CUI [1]
- C1827106
- UMLS CUI [2]
- C3273809
Beschrijving
Eligibility Criteria Study Protocol
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348563
Similar models
Eligibility Type 2 Diabetes NCT01518101
- StudyEvent: Eligibility
C0201976 (UMLS CUI [2])
C0017654 (UMLS CUI [3])
C1827106 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0014361 (UMLS CUI [2,2])
C0243071 (UMLS CUI [2,3])
C3273809 (UMLS CUI [2])
C2348563 (UMLS CUI [1,2])